These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6112118)

  • 41. Classification and psychotropic drugs.
    Shepherd M
    Prog Neuropsychopharmacol; 1980; 4(4-5):447-54. PubMed ID: 6111815
    [No Abstract]   [Full Text] [Related]  

  • 42. Pharmacological characterization of perifornical hypothalamic dopamine receptors mediating feeding inhibition in the rat.
    Leibowitz SF; Rossakis C
    Brain Res; 1979 Aug; 172(1):115-30. PubMed ID: 37990
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pre- and postsynaptic mechanisms in haloperidol-induced sensitization to dopaminergic agonists.
    Muller P; Svensson TH; Carlsson A
    Adv Biochem Psychopharmacol; 1980; 24():69-74. PubMed ID: 6105807
    [No Abstract]   [Full Text] [Related]  

  • 44. Antipsychotic substances and dopamine in the rat brain; behavioral studies reveal distinct dopamine receptor systems.
    Van Ree JM; Elands J; Király I; Wolterink G
    Eur J Pharmacol; 1989 Aug; 166(3):441-52. PubMed ID: 2572429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Could the interaction of neuroleptics with calmodulin be an "explanation" of the psychotropic effects?
    Lejoyeux M; Maziere JC
    Encephale; 1991; 17(1):11-5. PubMed ID: 1688272
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Two automated locomotor activity tests for dopamine autoreceptor agonists.
    Schreur PJ; Nichols NF
    Pharmacol Biochem Behav; 1986 Jul; 25(1):255-61. PubMed ID: 2875471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug interactions in psychiatry.
    Ban TA
    Int Pharmacopsychiatry; 1978; 13(2):94-9. PubMed ID: 27466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevention of neuroleptic-induced dopamine D2 receptor supersensitivity by chronic iron salt treatment.
    Ben-Shachar D; Pinhassi B; Youdim MB
    Eur J Pharmacol; 1991 Sep; 202(2):177-83. PubMed ID: 1687031
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of apomorphine-induced climbing in mice by cholinergic drugs and neuroleptics.
    Lassen JB
    Acta Pharmacol Toxicol (Copenh); 1979 Aug; 45(2):161-5. PubMed ID: 40391
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The quantitative measurement of changes in EEG frequency spectra produced in the cat by sedative-hypnotics and neuroleptics.
    Fairchild MD; Jenden DJ; Mickey MR; Yale C
    Electroencephalogr Clin Neurophysiol; 1980 Aug; 49(3-4):382-90. PubMed ID: 6158416
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lack of relation between dopaminergic and gabaergic mechanisms in chick retina.
    Nistico G; De Sarro A; Urna G; Pujia A; Ientile R
    Res Commun Chem Pathol Pharmacol; 1983 Apr; 40(1):29-39. PubMed ID: 6135247
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The effect of halothane anesthesia on dopamine release induced by apomorphine or haloperidol--an in vivo microdialysis study in rats striatum].
    Adachi Y; Wada H; Higuchi H; Watanabe K; Satoh T
    Masui; 2001 Oct; 50(10):1089-95. PubMed ID: 11712340
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in dopamine synthesis rate in the supersensitivity phase after treatment with a single dose of neuroleptics.
    Hyttel J
    Psychopharmacology (Berl); 1977 Jan; 51(2):205-7. PubMed ID: 14353
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in the sensitivity of receptors for neurotransmitters and the actions of some psychotherapeutic drugs.
    Richelson E; El-Fakahany E
    Mayo Clin Proc; 1982 Sep; 57(9):576-82. PubMed ID: 6125630
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
    Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
    J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evidence for an inhibitory presynaptic component of neuroleptic drug action.
    de Belleroche JS; Bradford HF
    Br J Pharmacol; 1981 Mar; 72(3):427-33. PubMed ID: 6114766
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 3-Methoxytyramine accumulation: effects of typical neuroleptics and various atypical compounds.
    Saller CF; Salama AI
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Oct; 334(2):125-32. PubMed ID: 2878374
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Iron modulates neuroleptic-induced effects related to the dopaminergic system.
    Ben-Shachar D; Livne E; Spanier I; Zuk R; Youdim MB
    Isr J Med Sci; 1993 Sep; 29(9):587-92. PubMed ID: 7901181
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of lesions in the ventral noradrenergic bundle on behavior and response to psychotropic drugs in rats.
    Jerlicz M; Kostowski W; Bidzinski A; Hauptmann M
    Pharmacol Biochem Behav; 1978 Dec; 9(6):721-4. PubMed ID: 34172
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of antipsychotics on presynaptic receptors modulating the release of dopamine in synaptosomes of the nucleus accumbens of rats.
    Hetey L; Drescher K
    Neuropharmacology; 1986 Oct; 25(10):1103-9. PubMed ID: 2878387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.